Xiong Y, Cheng L, Zhou YJ, Ge WH, Qian M, Yang H. Diagnosis and treatment of lung cancer: A molecular perspective. World J Clin Oncol 2025; 16(3): 100361 [DOI: 10.5306/wjco.v16.i3.100361]
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Mar 24, 2025; 16(3): 100361 Published online Mar 24, 2025. doi: 10.5306/wjco.v16.i3.100361
Diagnosis and treatment of lung cancer: A molecular perspective
Yuan Xiong, Long Cheng, Yu-Jie Zhou, Wei-Hong Ge, Ming Qian, Hui Yang
Yuan Xiong, Long Cheng, Wei-Hong Ge, Ming Qian, Hui Yang, Department of Pharmacy, Nanjing Drum Tower Hospital, Nanjing 210008, Jiangsu Province, China
Yuan Xiong, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China
Long Cheng, Nanjing Drum Tower Hospital Clinical College, Nanjing University of Chinese Medicine, Nanjing 210008, Jiangsu Province, China
Yu-Jie Zhou, Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, Nanjing 210008, Jiangsu Province, China
Co-first authors: Yuan Xiong and Long Cheng.
Co-corresponding authors: Ming Qian and Hui Yang.
Author contributions: Xiong Y and Cheng L wrote the draft; Zhou YJ and Ge WH revised the paper; Qian M and Yang H designed the overall concept and reviewed the manuscript. All authors read and approved the final manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Received: August 15, 2024 Revised: December 23, 2024 Accepted: January 9, 2025 Published online: March 24, 2025 Processing time: 159 Days and 6.6 Hours
Abstract
This editorial comments on the review by Da Silva et al, published in the World Journal of Clinical Oncology which focuses on the molecular perspectives of lung cancer. With the rapid development of molecular technology, new diagnostic methods are constantly emerging, including liquid biopsy, the identification of gene mutations, and the monitoring biomarkers, thus providing precise information with which to identify the occurrence and development of lung cancer. Biomarkers, such as circulating tumor cells, circulating tumor DNA, and circulating RNA can provide helpful information for clinical application. Common types of genetic mutations and immune checkpoints include epidermal growth factor receptor, anaplastic lymphoma kinase, c-ROS proto-oncogene 1, programmed death-1 and cytotoxic T-lymphocyte-associated protein. According to specific biomarkers, targeted therapy and immunotherapy can improve survival outcomes based on the types of gene mutation and immune checkpoints. The application of molecular approaches can facilitate our ability to control the progression of disease and select appropriate therapeutic strategies for patients with lung cancer.
Core Tip: The development of molecular biology techniques, including liquid biopsy techniques, the identification of gene mutations, and the application of immune checkpoint inhibitors can contribute to early and accurate diagnosis and personalized treatment strategies for lung cancer.
